{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 9,
  "pageCount": 28,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a three-column layout to categorize benefits.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/9",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In patients with treatment resistant major depressive disorder (MDD), who have not responded to at least 2 courses of appropriately administered oral antidepressants, a short course of Psilocybin Therapy provides greater and durable efficacy on depressive symptoms, significant improvement of functioning, as well as patient (and caregiver) health-related quality of life and reduced healthcare resource utilisation.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a217-c70cca5f601c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.06,
        "y": 0.4
      },
      "kind": "list",
      "text": "PATIENT BENEFIT: Faster and longer lasting relief from depressive symptoms; Significant improvement in social, family, & occupational functioning; Convenient experience, with no adherence concerns",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5830feac-6310-4b62-80ab-76356c417acd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.66,
        "y": 0.4
      },
      "kind": "list",
      "text": "ECONOMIC BENEFIT: More cost-effective, with reduced healthcare resource utilisation (HRU); Lower hospitalisation rates; Fewer outpatient visits; Delay/prevention of progression to more costly interventions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92eeac73-c117-48d0-b344-9b54975c7a4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.36,
        "y": 0.4
      },
      "kind": "list",
      "text": "THERAPEUTIC BENEFIT: Superior efficacy; More sustained/durable efficacy; Safe and well tolerated, with no significant adverse event associated with commonly prescribed antidepressants",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c46e690-7e8b-43d9-9f46-3fbe640b5521",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Value proposition: In patients with treatment resistant major depressive disorder (MDD), who have not responded to at least 2 courses of appropriately administered oral antidepressants, a short course of Psilocybin Therapy provides greater and durable efficacy on depressive symptoms, significant improvement of functioning, as well as patient (and caregiver) health-related quality of life and reduced healthcare resource utilisation.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2872b7ba-207f-414a-b50e-cd35d2b4445b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Based on early-stage clinical studies and high level economic analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "668a05b5-ee89-44a5-b1b6-be1ef58f78db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Psilocybin Therapy: Attractive Value Proposition in terms of therapeutic, patient, and economic benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a914dab3-46bb-4c25-901b-90d72408cdbf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Value Proposition Canvas",
      "slug": "value-proposition-canvas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "19d3d1b6-e29f-4cad-9423-ddf6a08cb9ed",
      "evidence": "The slide outlines the value proposition of psilocybin therapy, highlighting its therapeutic, patient, and economic benefits.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "554d3b9d-f4da-4b84-9feb-45a0d75afc78",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 8 and 9 agitate the problem by highlighting the breakthrough therapy designation for psilocybin and its potential benefits.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "2c026b6f-bde1-4704-bc90-2f6332879c93",
      "evidence": "The breakthrough therapy designation and potential for accelerated approval are highlighted.",
      "position": 1,
      "objective": "Explain why now is the time for psilocybin therapy",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}